Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study
| Autor: | Do‐Youn Oh, Alain Algazi, Jaume Capdevila, Federico Longo, Wilson Miller, Jerry Tan Chun Bing, Carlos Eduardo Bonilla, Hyun Cheol Chung, Tormod K. Guren, Chia‐Chi Lin, Daniel Motola‐Kuba, Manisha Shah, Julien Hadoux, Lili Yao, Fan Jin, Kevin Norwood, Loïc Lebellec |
|---|---|
| Přispěvatelé: | Institut Català de la Salut, [Oh DY] Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea. Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. [Algazi A] University of California San Francisco, San Francisco, California, USA. [Capdevila J] Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. IOB‐Quiron‐Teknon, Barcelona, Spain. [Longo F] Hospital Universitario Ramón y Cajal, IRYCIS, CIBERONC, Madrid, Spain. [Miller W Jr] Segal Cancer Centre, Jewish General Hospital, Rossy Cancer Network, Montreal, Quebec, Canada. Department of Oncology, McGill University, Montreal, Quebec, Canada. [Bing JTC] Cebu Doctors University Hospital, Cebu City, Province of Cebu, Philippines, Vall d'Hebron Barcelona Hospital Campus |
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: |
Cancer Research
Otros calificadores::/uso terapéutico [Otros calificadores] Medicaments antineoplàstics - Ús terapèutic Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS] Tiroide - Càncer - Tractament Other subheadings::Other subheadings::/drug therapy [Other subheadings] Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT] Oncology Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antineoplastic Agents Immunological [CHEMICALS AND DRUGS] Avaluació de resultats (Assistència sanitària) Other subheadings::/therapeutic use [Other subheadings] Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Thyroid Neoplasms [DISEASES] acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos::inmunoterapia antineoplásica [COMPUESTOS QUÍMICOS Y DROGAS] neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias de la tiroides [ENFERMEDADES] |
| Zdroj: | Scientia |
| Popis: | Immunotherapy; Pembrolizumab; Thyroid neoplasms Inmunoterapia; Pembrolizumab; Neoplasias de tiroides Immunoteràpia; Pembrolizumab; Neoplàsies de tiroides Background The authors report results from the thyroid carcinoma cohort of the multicohort phase 2 KEYNOTE-158 study (NCT02628067), which evaluated pembrolizumab monotherapy in patients with previously treated cancers. Methods Eligible patients had histologically and/or cytologically confirmed papillary or follicular thyroid carcinoma, failure of or intolerance to prior therapy, and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Patients received pembrolizumab (200 mg) every 3 weeks for up to 35 cycles. The primary end point was objective response rate (ORR) per RECIST v1.1 by independent central review. Results A total of 103 patients were enrolled and received pembrolizumab. Median duration from first dose to data cutoff (October 5, 2020) was 49.4 (range, 43.9–54.9) months. ORR was 6.8% (95% confidence interval [CI], 2.8%–13.5%), and median duration of response was 18.4 (range, 4.2‒47.2+) months. ORR was 8.7% (95% CI, 2.4%‒20.8%) among patients with programmed cell death ligand 1 (PD-L1) combined positive score (CPS) ≥1 (n = 46) and 5.7% (95% CI, 1.2%‒15.7%) among patients with PD-L1 CPS |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|